Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Review Extended Until June

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA wants more time to evaluate the risk management plan for the withdrawn multiple sclerosis drug.

You may also be interested in...



Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan

Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.

Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan

Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.

Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says

Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel